Based on the hypothesis that interruption of PD-1/PD-L1 binding may activate the tumor-specific T-cells, several types of immune checkpoint inhibitors (ICI) targeting PD-1 or its ligand have been approved for various cancer therapies [10]. This evidence concerns the gene PDCD1 and neoplasm.